Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Mulder, ChristiaanRupert, Stephan
Setiawan, Ery
Mambetova, Elmira
Edo, Patience
Sugiharto, Jhon
Useni, Sani
Malhotra, Shelly
Cook-Scalise, Sarah
Pambudi, Imran
Kadyrov, Abdullaat
Lawanson, Adebola
van den Hof, Susan
Gebhard, Agnes
Juneja, Sandeep
Sohn, Hojoon
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.Published in
BMJ global health 2022;7(1):e007182PMID
34992077ae974a485f413a2113503eed53cd6c53
10.1136/bmjgh-2021-007182
Scopus Count
Collections
Related articles
- Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
- Authors: Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, Lomtadze N, Avaliani Z, Kiria N, Malhotra S, Cook-Scalise S, Juneja S, Everitt D, Spigelman M, Vassall A
- Issue date: 2021 Dec 3
- Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
- Authors: Howell P, Upton C, Mvuna N, Olugbosi M
- Issue date: 2021 Dec 7
- Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies.
- Authors: Mota F, Ruiz-Bedoya CA, Tucker EW, Holt DP, De Jesus P, Lodge MA, Erice C, Chen X, Bahr M, Flavahan K, Kim J, Brosnan MK, Ordonez AA, Peloquin CA, Dannals RF, Jain SK
- Issue date: 2022 Dec 29
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
- Authors: Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D, Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A, Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel CM, Spigelman M, ZeNix Trial Team
- Issue date: 2022 Sep 1
- Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.
- Authors: Fekadu G, Yao J, You JHS
- Issue date: 2022